STAT+: Science Corp. raises $230 million to bring retinal implant to Americans

Science Corp. has successfully raised $230 million in funding as it prepares to bring its wireless retinal implant, known as PRIMA, to the American market. This significant financial backing comes as the company awaits a decision from the U.S. Food and Drug Administration (FDA) regarding the approval of the PRIMA device. The funding round has reportedly assigned Science Corp. a post-money valuation of $1.25 billion, indicating strong investor confidence in the company's potential and the technology it is developing. The PRIMA retinal implant is designed to restore vision for individuals suffering from certain types of blindness. The device operates wirelessly, which is a notable feature that distinguishes it from other retinal implants currently available or in development. The funding raised will likely support the final stages of development and the regulatory process as Science Corp. seeks to navigate the complexities of bringing a medical device to market in the United States. As the company moves forward, the outcome of the FDA's decision will be crucial for its plans. Approval from the FDA would not only validate the technology but also pave the way for commercialization and wider distribution of the PRIMA implant. The successful fundraising effort reflects the growing interest and investment in innovative medical technologies aimed at improving quality of life for patients with vision impairments.